Compare American Airlines Group Inc (AAL) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Airlines Group Inc vs Merck & Co., Inc. — how do they compare? American Airlines Group Inc trades at $16.58 (market cap $11.38B), while Merck & Co., Inc. trades at $125.26 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 28× American Airlines Group Inc's market cap, and Merck & Co., Inc. pays a 2.64% dividend while American Airlines Group Inc pays none. Which is the better fit depends on your goals.
| AAL | MRK | |
|---|---|---|
Market Cap | $11.38B | $318.26B |
Sector | Industrials | Health |
52-Week High | $18.15 | $129.52 |
52-Week Low | $10.18 | $77.60 |
Enterprise Value | $38.97B | $361.68B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Airlines (AAL) trades at $17.20, down 4.02% amid sector rotation. The stock shows a bullish technical signal with strong moving average alignment, though RSI levels are mixed. Fundamentally, revenue grew to $54.63B in 2025, but net income fell sharply to $111M, reflecting margin pressure. Recent news highlights airline sector volatility, with fuel cost declines offering relief but broader market sentiment weighing on travel stocks.
Outlook remains cautious; analyst consensus is split with a $19.96 price target suggesting modest upside. Key risks include volatile fuel prices, competitive pressures, and high debt levels. Earnings consistency is critical for sustained recovery, with Q2 2026 results pivotal for confirming operational improvements.
Merck (MRK) trades at $126.78, showing stable recent performance with strong institutional interest. The company demonstrates solid fundamentals with 2025 revenue of $65.01B and net income of $18.25B, representing a 28.07% profit margin. Recent earnings have consistently beaten expectations, and the company is actively expanding through strategic acquisitions like Terns Pharmaceuticals. Technical indicators show a bullish trend with moving averages supporting upward momentum, though oscillators suggest some consolidation may be needed.
Merck presents a compelling investment case with strong profitability, consistent earnings beats, and strategic pipeline expansion through M&A. The stock offers 9.9% upside to the consensus price target of $139.33, supported by 67.6% analyst buy ratings. Key risks include patent expirations, competitive pressures in oncology, and integration challenges from recent acquisitions. The company's robust cash flow generation supports continued dividend payments and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
